
[05a] In one aspect, set forth herein is a compound, or pharmaceutically acceptable solvate or stereoisomer thereof,

wherein the compound has a structure according to Formula (**IV**):



(**IV**)


wherein:

BA is a binding agent;

RG[1] and **RG[2]** are reactive group residues;

SP[1] and **SP[2]** are independently, in each instance, absent, or a spacer group residue;

HG is a hydrophilic residue selected from



and




wherein the indicates the atom through which the **HG** is bonded to the adjacent groups in the formula ;

PA is a payload residue;

AA[1] is a trivalent linker comprising an amino acid residue;

AA^2 is a dipeptide, tripeptide, or tetrapeptide residue;

PAB is  , wherein the  indicates the atom through which the **PAB** is bonded to the adjacent groups in the formula;

subscript **n** is an integer from 1 to 30;

subscript **p** is 0 or 1; and


subscript **q** is 0 or 1.

[05b] In another aspect, set forth herein, is a pharmaceutical composition comprising a compound as described herein, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[05c] In another aspect, set forth herein, is a compound as described herein, or a composition as described herein for use in treating a disease or disorder in a patient in need thereof.

[06] In another example, set forth herein, is a compound, including: a reactive group linked to at least one payload moiety and linked to at least one hydrophilic moiety via a covalent linker, wherein said covalent linker is bonded directly or indirectly to each of the reactive group, the payload moiety, and the hydrophilic moiety.

[06a] In another aspect, set forth herein, is a compound according to Formula (**VII**):




(VII)


LL is a trivalent linker;

RG′ is a reactive group;

RG² is a reactive group residue;

SP¹ and **SP²** are independently, in each instance, absent, or a spacer group residue;

HG is a hydrophilic residue selected from  and



;

PA is a payload residue; and

subscript **q** is 0 or 1;

wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.

[07] In another example, set forth herein is an antibody-drug conjugate having a compound, described above and herein, bonded to an antibody or an antigen binding fragment thereof.

[07a] In another aspect, set forth herein is an antibody-drug-conjugate comprising the compound as described herein bonded to an antibody, or an antigen binding fragment thereof.

[08] In another example, set forth herein is a method of treating a disease, condition, or disorder in a patient in need thereof including administering to the patient a compound set forth herein. Also provided is the use of a compound set forth herein for treating a disease, condition, or disorder set forth herein. Further provided is the use of a compound set forth herein for the manufacture of a medicament for treating a disease, condition, or disorder set forth herein. In some examples, the compound is an antibody-drug conjugate.

[08a] In another aspect, set forth herein is a compound or pharmaceutical composition as described herein for use in treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

[08b] In another aspect, set forth herein is a compound or pharmaceutical composition as described herein for use in the treatment of a proliferative disease in a subject.

[08c] In another aspect, set forth herein is a compound or pharmaceutical composition as described herein for use in the treatment of a metabolic disease in a subject.

[08d] In another aspect, set forth herein is a compound or pharmaceutical composition as described herein for use in the treatment of inflammation in a subject.

[08e] In another aspect, set forth herein is a compound or pharmaceutical composition as described herein for use in the treatment of a neurodegenerative disease in a subject.

[08f] In another aspect, set forth herein is use of a compound or pharmaceutical composition as described herein in the manufacture of a medicament for treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

[09] In another example, set forth herein is a method of preparing an antibody-drug conjugate including the step of contacting a binding agent with a linker-payload compound set forth herein under conditions suitable for forming a bond between the binding agent and the linker-payload compound.

[09a] In another aspect, set forth herein is a method of preparing a compound as described herein comprising the step of contacting a binding agent with a compound as described herein, under conditions suitable for forming a bond between the binding agent and the compound.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[010] FIG. 1 shows three different types of payload compounds.

[011] FIG. 2 shows a synthetic process for preparing compounds 1a, 1c, 1e, 1f, 1i, 1j, 1k, 1m, 1q, Ib, Id, Ie-1, If-1, IIb, IIId, IIIe, and IVb.

[012] FIG. 3 shows shows a synthetic process for preparing compounds 1h, 1l, Ig, and Ih-1.

[013] FIG. 4 shows a synthetic process for preparing payloads B and C.

[014] FIG. 5 shows a synthetic process for preparing payload D.

[015] FIG. 6 shows a general synthetic procedure A for preparing intermediates 3a, 3b, 3c, and 3g.

[016] FIG. 7 shows a general synthethic procedure for preparing intermediates 3d, and 3f.

[017] FIG. 8 shows a synthethic process for preparation of intermediate 3e.

[018] FIG. 9 shows a synthethic process for preparation of intermediate 4a.

[019] FIG. 10 shows a synthetic process for preparation of intermediate 4b.

[020] FIG. 11 shows a synthetic process for preparation of intermediates 5a-g.


[021] FIG. 11A shows a synthetic process for preparation of intermediate 10a.

CLAIMS

What is claimed is:

1. A compound, or pharmaceutically acceptable solvate or stereoisomer thereof,

wherein the compound has a structure according to Formula (**IV**):



(**IV**)


wherein:

BA is a binding agent;


RG^1 and **RG^2** are reactive group residues;

SP^1 and **SP^2** are independently, in each instance, absent, or a spacer group residue;

HG is a hydrophilic residue selected from



and




wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula;

PA is a payload residue;

AA^1 is a trivalent linker comprising an amino acid residue;

AA^2 is a dipeptide, tripeptide, or tetrapeptide residue;

PAB is  , wherein the  indicates the atom through which the **PAB** is bonded to the adjacent groups in the formula;

subscript **n** is an integer from 1 to 30;


subscript **p** is 0 or 1; and

subscript **q** is 0 or 1;

.

2. The compound of claim 1, wherein subscript **n** is 1, 2, 3 or 4.

3. The compound of claim 1, according to Formula (**III**):



(**III**)


wherein

LL is –**AA^1-AA^2-(PAB)$_p$-**


ring **A** is fused to the triazole and is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl;

wherein cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted with alkyl, -OH, or -N$\mathbf{R^aR^b}$, where each of $\mathbf{R^a}$ and $\mathbf{R^b}$ is alkyl or H.


4. The compound of claim 1, according to Formula (**IVa**), Formula (**IVb**) or Formula (**IVc**):



(**IVa**),




(**IVb**),




(**IVc**).

5. The compound of claim 4, wherein $\mathbf{AA^1}$ is lysine, glutamine, glutamic acid, or aspartic acid.


6. The compound of claim 4, according to Formula (**Va**), (**Vb**), (**Vc**) or (**Vd**) respectively:




(**Va**),



(**Vb),**



(**Vc**), or






















(**Vd**),

wherein:

subscript **e** is independently, in each instance, an integer from 0 to 6.


7. The compound of any one of claims 1 or 4-6, wherein **RG^1** and **RG^2** are independently in each instance, a click chemistry residue.

8. The compound of any one of claims 1 or 4-6, wherein **RG^1** and **RG^2** independently in each instance, comprise a triazaole or a fused triazole.

9. The compound of any one of claims 1 or 4-8, wherein **RG[1]** and **RG[2]** are independently, in each instance, selected from the group consisting of , , , , , , , , , , , or , , , , , , , and ,


wherein the  indicates the atom through which the **RG[1]** or **RG[2]** is bonded to the adjacent groups in the formula.

10. The compound of any one of claims 1 or 4-9, wherein **HG** is



wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.


11. The compound of any one of claims 1 or 4-9, wherein **HG** is




, wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.

12. The compound of any one of claims 1, 4-5, and 7-11, wherein **SP^1** and **SP^2** are independently, in each instance, absent, or selected from the group consisting of C_{1-6} alkylene, -NH-, -C(O)-, $(-CH_2-CH_2-O)_e$, -NH-CH_2-CH_2-$(-O-CH_2-CH_2)_e$-C(O)-, -C(O)-$(CH_2)_u$-C(O)-, -C(O)-NH-$(CH_2)_v$-, $(glycine)_4$-serine, and combinations thereof, wherein subscript **e** is an integer from 0 to 4, subscript **u** is an integer from 1 to 8, and subscript **v** is an integer from 1 to 8.


13. The compound claim 1, wherein





is selected from the group consisting of:





,



,



,


,



,


,



,




,




,




,



,




,



,

and




,

or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein


each  is a bond to the binding agent; and

each  is a bond to the payload residue.


14. The compound of claim 1, wherein




is selected from the group consisting of:





,



,


, and


,



,

or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each  is a bond to the binding agent; and

each  is a bond to the payload residue.


15. The compound of claim 3, wherein **LL** is according to Formula (**LL1**):


(**LL1**)

wherein $\mathbf{R^{AA1}}$, $\mathbf{R^{AA2}}$, and $\mathbf{R^{AA3}}$ are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to $\mathbf{-(RG^2)_q\text{-}SP^2\text{-}HG}$


16. The compound of claim 15, wherein $\mathbf{R^{AA1}}$ is a lysine, glutamine, glutamic acid or aspartic acid side chain bonded directly or indirectly to **HG**, and $\mathbf{R^{AA2}}$ and $\mathbf{R^{AA3}}$ are either valine and alanine or valine and citrulline sidechains respectively.

17. The compound of any one of claims 1 or 4-6, wherein **AA^2** is




wherein **R^{AA2}**, **R^{AA3}**, **R^{AA4}**, and **R^{AA5}** are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to **–(RG^2)$_q$-SP^2-HG**, wherein the  indicates the atom through which **AA^2** is bonded to the adjacent groups in the formula.

18. The compound of any one of claims 1 or 4-6, wherein **AA^2** is



or



,

wherein the  indicates the atom through which **AA^2** is bonded to the adjacent groups in the formula.

19. The compound of any one of claims 6-12, wherein subscript e is 4.


20. The compound of any one of claims 1-19, wherein the binding agent (**BA**) is an antibody or antigen-binding fragment thereof.

21. The compound of any one of claims 1-19, wherein the binding agent (**BA**) is an antibody, or an antigen-binding fragment thereof, selective for an antigen selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2, BTNL3, BTNL8, BTNL9, C10 or f54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25, CD27, CD274, CD276,


CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD46, CD48, CD5, CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2, CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1/2, CXCR4, CXCR5, DDR1, DDR2, DEC-205, DLL4, DR6, FAP, FCamR, FCMR, FcR's, Fire, GITR, HHLA2, HLA class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, IL22R1, IL22RA, IL23R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, IL5R, IL7R, IL9R, Integrins, LAG3, LIFR, MAG/Siglec-4, MMR, MSR1, NCR3LG1, NKG2D, NKp30, NKp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1, Siglec-10, Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, SIRPA, SLAMF7, TACI, TCR-list components/assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4, and VTCN1.

22. The compound of any one of claims 1-21, wherein **PA** is the residue of a group selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a plant alkaloid, a taxane, a vinca alkaloid, a steroid, and a liver X receptor (LXR) modulator.


23. The compound of any one of claims 1 and 20-22, selected from the group consisting of:




,



,




,



,

and



,


or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each **Ab** is an antibody, or an antigen-binding fragment thereof;


PA is a payload residue; and


subscript **n** is an integer from 1 to 30.


24. The compound of any one of claims 1 and 20-21, selected from the group consisting of:




,


Ab
n



Ab
n


Ab
n


,




,





,



Ab
n

,



Ab
n


Ab
n



Ab
n


Ab
n


,




,




,




,



Ab
n

,



Ab
n

,



Ab
n



Ab
n

,



Ab
n

,






,




,



,


and



or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each **Ab** is an antibody, or an antigen-binding fragment thereof; and
subscript **n** is an integer from 1 to 30.


25. The compound of any one of claims 1-24, wherein **BA** is a modified antibody of formula (**Ab-1**)




(**Ab-1**)

wherein the  indicates the atom through which **Ab-1** is bonded to the adjacent groups in the formula.


26. The compound of claim 25, selected from the group consisting of:




,




,




,


Ab
SO3H
n


,


Ab
SO3H
n


,




,




,




,



Ab
N
H
HN
O
HO
F
HN
SO3H
n


,



Ab
N
H
HN
O
HO
F
NH2
HN
SO3H
n

,











Ab
F
H
H
F
O
OH
HN
SO3H
n


,



Ab
F
H
H
F
O
OH
NH2
HN
SO3H
n

,











Ab
N
H
O
O
O
N
N
N
H
O
O
O
O
O
O
O
H
N
O
O
H
N
O
H
N
O
N
H
O
H
N
O
H
N
O
OH
HN
O
O
N
N
N
O
O
O
O
O
O
HN
SO3H
n


,



Ab
N
H
O
O
O
N
N
N
H
O
O
O
O
O
O
O
H
N
O
O
H
N
O
H
N
O
N
H
O
H
N
O
H
N
O
OH
N
H
NH2
O
HN
O
O
N
N
N
O
O
O
O
O
O
HN
SO3H
n






,





,

and



,


or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each **Ab** is an antibody, or an antigen-binding fragment thereof; and
subscript **n** is an integer from 1 to 30.

27. A pharmaceutical composition comprising a compound of any one of claims 1-26, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

28. A compound of any one of claims 1-26, or a composition of claim 27 for use in treating a disease or disorder in a patient in need thereof.

29. A compound according to Formula (**VII**):




(VII)


LL is a trivalent linker;

RG′ is a reactive group;

RG^2 is a reactive group residue;

SP^1 and **SP^2** are independently, in each instance, absent, or a spacer group residue;

HG is a hydrophilic residue selected from  and



;

PA is a payload residue; and

subscript **q** is 0 or 1;

wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.

30. The compound of claim 29, according to Formula (**VIII**):



(**VIII**)


wherein

LL is –$\mathbf{AA^1}$-$\mathbf{AA^2}$-$\mathbf{(PAB)_p}$,

ring **A** is fused to the triazole and is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl;

wherein cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted with alkyl, -OH, or -N$\mathbf{R^aR^b}$, where each of $\mathbf{R^a}$ and $\mathbf{R^b}$ is alkyl or -H.

31. The compound of claim 29, according to Formula (**IX**):




(**IX**)

wherein:

AA^1 is a trivalent linker comprising an amino acid residue;


AA^2 is a dipeptide, tripeptide or tetrapeptide residue; and

PAB is , wherein the  indicates the atom through which the PAB is bonded to the adjacent groups in the formula;


subscript **p** is 0 or 1; and

subscript **q** is 0 or 1.


32. The compound of claim 31, according to Formula (**IXa**), Formula (**IXb**) or Formula (**IXc**):



(**IXa**),




(**IXb**),




(**IXc**).

33. The compound according to claim 32, wherein **AA^1** is lysine, glutamine, glutamic acid, or aspartic acid.


34. The compound of claim 32, according to Formula (**Xa**), (**Xb**), (**Xc**), or (**Xd**):




(**Xa**)



(**Xb**)



(**Xc**), or





(**Xd**),


wherein:

subscript **e** is independently, in each instance, an integer from 0 to 6.


35. The compound of any one of claims 30-34, wherein **RG′** is, independently in each instance, a click chemistry residue.

36. The compound of any one of claims 30-34, wherein **RG′** is, independently in each instance, selected from the group consisting of 


, 

and 

, wherein the  indicates the atom through which the **RG′** is bonded to the adjacent groups in the formula.

37. The compound of any one of claims 30-36, wherein **RG²** is independently, in each instance, selected from the group consisting of 


,



, and ,

wherein the  indicates the atom through which the **RG²** is bonded to the adjacent groups in the formula.


38. The compound of any one of claims 30-37, wherein **HG** is



wherein

the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.


39. The compound of any one of claims 30-37, wherein **HG** is




, wherein the  indicates the atom through which the **HG** is bonded to the adjacent groups in the formula.

40. The compound of any one of claims 30-33 and 35-39, wherein **SP^1** and **SP^2** are independently, in each instance, absent, or selected from the group consisting of C_{1-6} alkylene, -NH-, -C(O)-, $(-CH_2-CH_2-O)_e$, -NH-CH_2-CH_2-$(-O-CH_2-CH_2)_e$-C(O)-, -C(O)-$(CH_2)_u$-C(O)-, -C(O)-NH-$(CH_2)_v$-, $(glycine)_4$-serine, and combinations thereof, wherein subscript **e** is an integer from 0 to 4, subscript **u** is an integer from 1 to 8, and subscript **v** is an integer from 1 to 8.


41. The compound of claim 31, wherein





is selected from the group consisting of:





,



,








,



,


,


,


,


,

,

,

,

,

,
and




,


or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each  is a bond to the payload residue.


42. The compound of claim 31, wherein




is selected from the group consisting of:




,



,




,



,

and




,

or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein

each  is a bond to the payload residue.


43. The compound of claim 29, wherein **LL** is according to Formula (**LL1**):


(**LL1**)

wherein $\mathbf{R^{AA1}}$, $\mathbf{R^{AA2}}$, and $\mathbf{R^{AA3}}$ are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to $\mathbf{-(RG^2)_q\text{-}SP^2\text{-}HG}$



44. The compound of claim 43, wherein $\mathbf{R^{AA1}}$ is a lysine, glutamine, glutamic acid or aspartic acid side chain bonded directly or indirectly to **HG**, and $\mathbf{R^{AA2}}$ and $\mathbf{R^{AA3}}$ are either valine and alanine or valine and citrulline sidechains respectively.

45. The compound of any one of claims 31-40, wherein $\mathbf{AA^2}$ is



wherein $\mathbf{R^{AA2}}$, $\mathbf{R^{AA3}}$, $\mathbf{R^{AA4}}$, and $\mathbf{R^{AA5}}$ are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to $\mathbf{-(RG^2)_q\text{-}SP^2\text{-}HG}$, wherein the  indicates the atom through which $\mathbf{AA^2}$ is bonded to the adjacent groups in the formula.

46. The compound of any one of claims 31-40, wherein $\mathbf{AA^2}$ is



or

,


wherein the  indicates the atom through which **AA^2** is bonded to the adjacent groups in the formula.

47. The compound of any one of claims 34-40, wherein subscript **e** is 4.


48. The compound of any one of claims 29-47, wherein **PA** is the residue of a group selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a plant alkaloid, a taxane, a vinca alkaloid, a steroid, and a liver X receptor (LXR) modulator.


49. The compound of claim 29, selected from the group consisting of:






,



PA
SO3H



PA
NH2
SO3H


or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein **PA** is a payload residue.

50. The compound of claim 29, selected from the group consisting of:



,


,



,




,




,




,





,




,









,





,




,









,







,




,




,




,




,




,



,



and



or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof.

51. A method of preparing a compound of claim 1 comprising the step of contacting a binding agent with a compound according to any of claim 29-50, under conditions suitable for forming a bond between the binding agent and the compound.

52. The method of claim 51, wherein the binding agent is a modified binding agent comprising an azido group ($\overset{\sim}{\sim}N_3$) wherein the $\overset{\sim}{\sim}$ indicates the atom through which the azido group is bonded to the adjacent groups in the formula.

53. The compound of claim 29 wherein LL is bonded to an oxygen or a primary or secondary nitrogen of the payload.

54. An antibody-drug-conjugate comprising the compound of any of claims 29-50 bonded to an antibody, or an antigen binding fragment thereof.

55. A compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 for use in treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

56. A compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 for use in the treatment of a proliferative disease in a subject.

57. A compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 for use in the treatment of a metabolic disease in a subject.

58. A compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 for use in the treatment of inflammation in a subject.

59. A compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 for use in the treatment of a neurodegenerative disease in a subject.

60. Use of a compound of any one of claims 1-28 or a pharmaceutical composition of claim 29 in the manufacture of a medicament for treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.